EBS Emergent BioSolutions Inc.

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
EN
08/10/2020

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Recognizes Several Important Observances to Help...

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) today recommitted to its leadership combating the opioid crisis through a multi-faceted approach focused on awareness, education and widespread access to naloxone, including NARCAN® Nasal Spray 4 mg and KLOXXADO® (naloxone...

September 24, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Secures $29 Million in MCM Product Orders from I...

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent’s medical countermeasures (MCM) business, including countermeasures for smallpox, anthrax and botulism threats, and reflects the increasing priority governments are placing on defense ...

September 19, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Secures $17 Million Contract Modification for Or...

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension...

September 15, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives New Contract Modification for ACAM2000®...

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancil...

September 9, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Awarded $30 Million Contract Modification for CY...

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch